• Analyzing the pro and cons of using the ITC in a Hatch-Waxman related pharmaceutical patent challenge
• Examples of such proceedings and other lifesciences related proceedings where the ITC has been utilized
• Determining if ITC 337 petitions are a viable means of protecting the patent life of pharmaceutical products in a Hatch-Waxman scenario

Speakers:
Wanda D. French-Brown, Partner, Fox Rothschild LLP
Brian Anderson, V.P. & Assist. General Counsel, Allergan
Sheila N. Swaroop, Partner, Knobbe, Martens, Olson & Bear LLP